We acquire, develop, own and operate the largest privately-held portfolio of science-based real estate concentrated within the core science submarkets of Boston, Massachusetts.

What We Do

Acquisitions

Whether through a bid process or by an off-market transaction, our team has a proven track record of identifying and acquiring properties in established locations that can serve the needs of science-based companies.

Development

Post-acquisition, we have the deep technical expertise and capital structure to creatively re-develop existing structures to the serve the needs of tenants in the rapidly growing sectors of life science and clean technology. We also pursue select ground-up development where we see opportunity to add new space to markets with strong life science demand.

Management

Our property management team operates and manages our assets to provide cost effective work environments for our tenants.

Leasing

Our leasing success is unmatched in the greater Boston marketplace due to relationships the company has developed over decades in the local market.

Investing With KSP

King Street has a proven track record of delivering superior risk-adjusted returns through its value-add and core-plus investments in the life science real estate sector. Whether for value-add or core-plus, King Street invests only in or near established life science nodes. The company is extremely active in the core science submarkets of Boston including Cambridge, Waltham and Lexington.

VALUE ADD

Value add projects – generally with an investment minimum of $20 million – require structures readily convertible to lab use.  King Street purchases vacant buildings for immediate conversion and leased buildings for later conversion at lease rollover.

CORE-PLUS

For core-plus acquisitions, King Street purchases existing lab buildings – generally with an investment minimum of $50 million.  Core returns from current-income need to be coupled with leasing or repositioning upside and/or future development capacity.

Placemaking. For Science.